1. Show article details.

    New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Business Wire – 8:00 AM ET 10/13/2021

    -- Findings presented at ECTRIMS 2021 suggest that deep, persistent B-cell depletion is linked to reduced disease activity -- Horizon Therapeutics plc (HZNP) today announced results from a new analysis of the UPLIZNA pivotal Phase 2/3 N-MOmentum trial indicating a correlation between the depth of B-cell depletion and improved NMOSD patient outcomes.

  2. Show article details.

    New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

    Business Wire – 9:00 AM ET 10/12/2021

    -- Highlights include a poster presentation about real-world adherence to TEPEZZA and an oral presentation sharing data from the OPTIC-X extension trial in people with Thyroid Eye Disease who have low-level inflammation -- Horizon Therapeutics plc (HZNP) today announced new TEPEZZA data will be presented at the American Academy of Ophthalmology Annual Meeting in New Orleans and virtually, Nov. 12-15, ...

  3. Show article details.

    Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021

    Business Wire – 8:00 AM ET 10/11/2021

    Horizon Therapeutics plc (HZNP) announced today that its third-quarter 2021 financial results will be released on Wednesday, Nov. 3, 2021. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast.

  4. Show article details.

    Horizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption

    Business Wire – 8:00 AM ET 10/06/2021

    Horizon Therapeutics plc (HZNP) today announced that is has been named one of the Top 100 Adoption-Friendly Workplaces in the United States by the Dave Thomas Foundation for Adoption for the third year in a row. “Adoption has the ability to positively change a child’s life – I know this to be true because it changed mine,” said Tim Walbert, chairman, president and chief executive officer, Horizon.

  5. Show article details.

    New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Business Wire – 8:30 AM ET 10/04/2021

    -- Data show notable decline in disease-related attacks after the first year of treatment in patients receiving UPLIZNA for four or more years -- -- Consistent safety profile maintained throughout long-term study period with no treatment discontinuations -- DUBLIN---- Horizon Therapeutics plc (HZNP) today announced the publication of a post-hoc analysis from the N-MOmentum phase 2/3 pivotal trial of U...

  6. Show article details.

    Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2021

    Business Wire – 8:00 AM ET 10/04/2021

    -- Presentations will feature analyses from the pivotal N-MOmentum study and the role of B-cell depletion in NMOSD disease activity reduction -- Horizon Therapeutics plc (HZNP) today announced that new UPLIZNA and NMOSD data analyses will be presented at the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2021, Oct. 13-15.

  7. Show article details.

    Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day

    Business Wire – 7:00 AM ET 09/29/2021

    -- Announcing Five Total New Development Programs for Daxdilimab and Dazodalibep; Expect to Initiate New Phase 2 Trials in 2022, Bringing Total Development Programs to 27 -- --Positioned for Growth with Expanding R&D Team, New Disease Areas and Manufacturing Capability-- -- 10 Data Readouts Across Development Programs Expected Through 2023 -- -- Robust Pipeline and Diversified Portfolio Represe...

  8. Show article details.

     Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021

    Business Wire – 9:00 AM ET 09/23/2021

     -- Event Begins at 9 a.m. ET -- Horizon Therapeutics plc (HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021.

  9. Show article details.

    BRIEF-Horizon Therapeutics Says Uplizna Also Produces Rapid And Sustained B-Cell Depletion In African Americans With NMOSD

    Reuters – 8:42 AM ET 09/23/2021

    Horizon Therapeutics PLC (HZNP): * HORIZON THERAPEUTICS PLC ANNOUNCES DATA SHOWING UPLIZNA ALSO PRODUCES RAPID AND SUSTAINED B-CELL DEPLETION IN AFRICAN AMERICANS WITH NMOSD Source text for Eikon: Further company coverage:

  10. Show article details.

    Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Business Wire – 8:30 AM ET 09/23/2021

    -- Analysis of 20 African Americans from the pivotal study presented at the 15th World Congress on Controversies in Neurology -- Horizon Therapeutics plc (HZNP) today announced results of a retrospective analysis of the pivotal Phase 2/3 N-MOmentum clinical trial, indicating UPLIZNA may provide durable efficacy and a favorable safety profile for African Americans with NMOSD.

  11. Show article details.

    BRIEF-Hemoshear Therapeutics Advancing Several Novel Compounds For Horizon Therapeutics PLC

    Reuters – 7:57 AM ET 09/21/2021

    Horizon Therapeutics PLC (HZNP): * HEMOSHEAR THERAPEUTICS ADVANCING SEVERAL NOVEL COMPOUNDS FOR HORIZON THERAPEUTICS PLC GOUT DISCOVERY PIPELINE. * HEMOSHEAR - SUCCESSFUL DEVELOPMENT & COMMERCIALIZATION OF THERAPIES BY HORIZON WILL MAKE CO ELIGIBLE FOR PAYMENTS OF POTENTIALLY MORE THAN $500 MILLION PLUS ROYALTIES Source text for Eikon: Further company coverage:

  12. Show article details.

    HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline

    PR Newswire – 7:30 AM ET 09/21/2021

    CHARLOTTESVILLE, Va., Sept. 21, 2021  HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics (HZNP) plc.

  13. Show article details.

    Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work®

    Business Wire – 9:00 AM ET 09/16/2021

    Horizon Therapeutics plc (HZNP) today announced that it has been named to the 2021 Best Workplaces for Women™ list for the first time by Fortune and Great Place to Work®. The Best Workplaces for Women award spotlights the top U.S. companies who have made a commitment to fostering equity in the workplace by ensuring women employees can reach their full potential.

  14. Show article details.

     Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)

    Business Wire – 8:30 AM ET 09/07/2021

    Horizon Therapeutics plc (HZNP) today announced that the first patient has been enrolled in a Phase 4 clinical trial evaluating the efficacy and safety of TEPEZZA for the treatment of chronic TED.

  15. Show article details.

    Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®

    Business Wire – 9:10 AM ET 09/01/2021

    Horizon Therapeutics plc (HZNP) today announced that it has been named to PEOPLE's 100 Companies That Care® 2021 list for the third year by PEOPLE and Great Place to Work®. The PEOPLE Companies that Care list spotlights the top U.S. companies who have succeeded in business while also demonstrating outstanding respect, care and concern for their employees, their communities and the environment.

  16. Show article details.

    Horizon Therapeutics plc to Participate in Upcoming Conferences

    Business Wire – 4:01 PM ET 08/23/2021

    Horizon Therapeutics plc (HZNP) today announced that the Company will participate in the following conferences: Handelsbanken Life Science Innovation Day 2021 Morgan Stanley 19th Annual Global Healthcare Conference The conference presentations will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay of each webcast will be available followin...

  17. Show article details.

    Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance

    Business Wire – 7:00 AM ET 08/04/2021

    -- Record Second-Quarter 2021 Net Sales of $832.5 Million Increased 80 Percent; Second-Quarter 2021 GAAP Net Income of $158.1 Million; Adjusted EBITDA of $366.9 Million -- -- Record TEPEZZA® Second-Quarter 2021 Net Sales of $453.3 Million Driven by Strong Demand and Relaunch Execution; Increasing Full-Year 2021 Net Sales Guidance to Greater Than $1.550 Billion and Expect Fourth-Quarter Year-Ove...

Page:

Today's and Upcoming Events

  • Nov
    03

    HZNP to announce Q3 earnings (Confirmed)

Past Events (last 90 days)

  • Aug
    04

    HZNP announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.